Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. The board of directors is pleased to announce that a three-arm parallel controlled phase II clinical study of GFH375 (oral KRAS G12D ON/OFF inhibitor) has recently begun. GFH375 will enter a phase II study of two novel combination therapies versus monotherapy to treat patients with KRAS G12D mutant locally advanced unresectable or metastatic pancreatic cancer. This multi-center, open-label, randomized controlled study will be conducted at dozens of centers in mainland China. The lead center is Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine; the two joint programs included in the study are GFH375 combined with the world's first cachexic dual antibody GFS202A (GDF15/IL-6 double antibody), and GFH375 in combination with GFH276 (pan-RAS ON inhibitor). In February 2026, GFH375/VS-7575 was the first in China to be certified as a breakthrough treatment for KRAS G12D mutant metastatic pancreatic cancer with a single drug, and was granted fast-track certification by the US FDA in 2025 to treat KRAS G12D mutant metastatic pancreatic ductal adenocarcinoma (PDAC).

Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. The board of directors is pleased to announce that a three-arm parallel controlled phase II clinical study of GFH375 (oral KRAS G12D ON/OFF inhibitor) has recently begun. GFH375 will enter a phase II study of two novel combination therapies versus monotherapy to treat patients with KRAS G12D mutant locally advanced unresectable or metastatic pancreatic cancer. This multi-center, open-label, randomized controlled study will be conducted at dozens of centers in mainland China. The lead center is Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine; the two joint programs included in the study are GFH375 combined with the world's first cachexic dual antibody GFS202A (GDF15/IL-6 double antibody), and GFH375 in combination with GFH276 (pan-RAS ON inhibitor). In February 2026, GFH375/VS-7575 was the first in China to be certified as a breakthrough treatment for KRAS G12D mutant metastatic pancreatic cancer with a single drug, and was granted fast-track certification by the US FDA in 2025 to treat KRAS G12D mutant metastatic pancreatic ductal adenocarcinoma (PDAC).